ArticleFrontiers in medicine2026
Sudden suspected anaphylactic shock after multiple tolerated doses of piperacillin-tazobactam: a case report and literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most well-known adverse reaction of penicillins is anaphylactic shock, which mostly occurs within the first few minutes of the initial administration. However, cases of sudden anaphylactic shock that develop after multiple consecutive doses with no prior adverse events are extremely rare. Case presentation: This report presents a case of sudden suspected anaphylactic shock in a 20-month-old toddler following several consecutive days of uneventful administration of piperacillin-tazobactam. Conclusion: This case underscores that the sensitization phase of β-lactam antibiotics may remain occult throughout the entire course of treatment. The absence of severe adverse reactions during early drug administration does not eliminate subsequent hypersensitivity risks, which emphasizes the imperative for clinicians to implement rigorous monitoring during each administration to safeguard pediatric medication safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.